Return to homepagePandemic Pact

Task V12: Clinical Sample Testing for SARS-CoV-2 Vaccine Candidates

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 272201800013I-0-759302000006-1

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2020
    2022

  • Known Financial Commitments (USD)

    $6,398,512

  • Funder

    National Institutes of Health (NIH)

  • Principal Investigator

    THOMAS RUDGE

  • Research Location

    United States of America

  • Lead Research Institution

    BATTELLE CENTERS/PUB HLTH RES & EVALUATN

  • Research Priority Alignment

    N/A

  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Diagnostics

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Not applicable

Abstract

The Evaluation and Testing Services (ETS) for Vaccines and Other Biologics for Infectious Diseases contract provides a variety of product development services from early feasibility studies through manufacture of Phase I/II material, including assay development; immunogenicity and efficacy testing; clinical and nonclinical sample testing; and safety and toxicity testing. These services will facilitate the development and introduction of new vaccines and biologics against potential agents of bioterrorism and emerging and re-emerging infectious diseases.